Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...

(Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...